Liminatus Pharma, Inc. Class A Common Stock
LIMNEarnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-1.50 | — | — | — |
| May 15, 2026 | $-0.03 | — | — | — |
| Mar 31, 2026 | $-0.03 | — | — | — |
| Nov 13, 2025 | $-0.07 | — | — | — |
| Oct 3, 2025 | $0.24 | — | — | — |
| May 31, 2025 | $-127.50 | — | — | — |
News
FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq's minimum bid price rule.
FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd.
FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value $0.0001 per share (“Common Stock”), at a ratio of 1-for-50 (the “Reverse Stock Split”), which was approved by stockholders at the Company's 2026 Annual Meeting of Stockholders held on August 3, 2026.
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the “Panel”) has granted the Company additional time to demonstrate compliance with Nasdaq's minimum bid pr…